We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Systems Improve Outcomes for Microbiology Labs

By HospiMedica staff writers
Posted on 30 May 2007
New automated systems have been designed to improve outcomes for busy microbiology labs.

The new systems were demonstrated by Magellan Biosciences' (Chelmsford, MA, USA) subsidiaries Trek Diagnostic Systems (Cleveland, OH, USA) and Dynex Technologies (Chantilly, VA, USA) at the American Society of Microbiology (ASM) meeting, which was held in Toronto (Canada) from May 22-24, 2007. More...


Trek launched its Vizion system, which adds digital-imaging capability to the company's Aris 2X automated Sensititre System with SWIN (Sensititre for Windows) software, to enable easy and accurate antimicrobial-resistance detection of all organism groups, including fastidious isolates that elude other automated systems.

Magellan president and CEO, Robert J. Rosenthal, Ph.D. said, "Trek's Vizion System enables surefire results through enhanced lighting options and on-screen display of large, easy-to-read digital images--with quantitative [minimum inhibitory concentration] and qualitative results--color-coded to eliminate questionable readings and errors [red/resistant, yellow/intermediate, and green/susceptible]. A touch-screen capability allows real-time recording of results, and Vizion enables users to save and store images for sharing, teaching, and comparison. The SWIN controlling software, which incorporates the latest CLSI [Clinical Laboratory and Standards Institute] guidelines and epidemiology reporting capabilities, eradicates mistakes from manual data transcription--and laboratories can integrate the system directly into their existing laboratory information system [LIS]--to make reporting of results data easy.”

Dynex featured its DS2 automated two-plate enzyme-linked immunosorbent assay (ELISA) processing system at the meeting. Dr. Rosenthal commented, "Dynex began shipments of the DS2 this month to ELISA kit manufacturers around the world to meet the needs of labs that don't have the throughput needs to justify large-scale systems on the market. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power in the smallest footprint available. The system quickly and easily processes two 96-well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics. An open system, the DS2 delivers sample-in/results-out automation of virtually any ELISA microplate assay.”


Related Links:
Magellan Biosciences
Trek Diagnostic Systems
Dynex Technologies

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Glucose Meter
StatStrip®
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.